Barroilhet discusses PARP inhibitors with OncLive

Lisa Barroilhet, MD, MS, associate professor in the Division of Gynecologic Oncology, joined OncLive to talk about the role of PARP inhibitors for patients with ovarian cancer.  

In the video, Barroilhet discusses findings from two trials that seem encouraging for PARP inhibitor use: 

“All patients with ovarian cancer displaying somatic or germline BRCA mutations should receive upfront PARP inhibitor maintenance therapy after completing an initial 6 cycles of chemotherapy with paclitaxel and carboplatin, Barroilhet says.... 

Patients with ovarian cancer with homologous recombination deficiency (HRD) may also benefit from PARP maintenance therapy, according to Barroilhet.” 

Watch the whole video here!